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A b s t r a c t:  
 
A novel series of cyrhetrenyl (3a-4a) and ferrocenyl (3b-4b) Schiff bases were synthesized 
through a condensation reaction, between the known 4-ferrocenylaniline (2b) or the 
unreported 4-cyhretrenylaniline (2a) with 4- or 5-nitrothiophenecarboxaldehyde. The 
structure of 2a and the new Schiff bases have been elucidated using conventional 
spectroscopic techniques (FT-IR, 1H and 13C NMR), mass spectrometry, and single-crystal 
X-ray diffraction analysis of compounds 2a, 4a and 3b. Cyclic voltammetry of 
organometallic phenylimines derived from 5-nitrothiphene showed NO2 group reduction 
potentials (E1/2 ≈ -0.575 V) that were more anodic than those registered for their 4-nitro 
analogues (E1/2 ≈ -0.981 V). All organometallic imines were tested against the bloodstream 
form of Trypanosoma brucei. Evaluation indicated that the most active complexes are the 
5-nitrothiophene derivatives, 4a, which were remarkably more active than nifurtimox. In 
addition, complex 4b resulted in less toxicity to host L6 cells than nifurtimox. The results 
revealed that the electronic effects of cyrhetrene a d ferrocene are not an influential factor 
in E1/2 and anti-Trypanosoma brucei activity for these new imines, which is probably due to 
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Neglected tropical diseases (NTDs) represent a collection of infections prevalent in 
many regions of the developing World. They are respon ible for substantial global 
morbidity, mortality, and economic adversity that together affect about 1 billion people 
worldwide [1]. One such infection is African trypanosomiasis, a debilitating condition 
caused by the tsetse fly-transmitted protozoan parasite Trypanosoma brucei (T. brucei) that 
is prevalent across sub-Saharan Africa [2]. In addition to affecting an estimated 70 million 
individuals living in endemic sites [2,3], this pathogen also is of veterinary and economic 
importance, being one of several trypanosomes responsible for a wasting disease known as 
Nagana in ungulate animals. 
 
At present, pentamidine, suramin, melarsoprol and eflornithine are the only drugs 
available to treat the human form of the disease, although there are signficiant issues 
relating to toxicity, administration, the disease stage being traeted and the T. brucei 
subspecies being targeted [4]. Additionally, due to long periods of treatment, the 
subsequent lack of completion of the treatment course and strain variation, resistance is 
emerging as a major problem [5]. Recently, the WHO added nifurtimox (Nfx), a 
nitroheterocycle normally used against Chagas disease, to the Essential Medicines list 
(EML) as part of the nifurtimox-eflornithine combination therapy (NECT) for treatment of 
T. brucei gambiense [2,6]. This recommendation, together with several merging reports on 
new nitroheterocyclic compounds with potential or significant in vitro activity against 
Trypanosoma cruzi (T. cruzi) and T. brucei, has reinvigorated interest in the use of 
nitroheterocyclic compounds as antitrypanosomal agents [7-12]. 
 
With the aim to find new and more efficient antitrypanosomal agents, inorganic 
compounds containing nitroaromatic systems have also been extensively explored [13-15]. 
The focus has been oriented mainly toward the protozoa T. cruzi, the caustive agent of 
American trypanosomiasis (also known as Chagas Disease) and to a lesser extent to T. 
brucei. The strategy consists in the coordination of a trnsition metal of known 















approach, the pioneering work of Sanchez-Delgado [16-18] and Gambino [19-21] can be 
cited as remarkable examples in the search for new antitrypanosomal agents. For example, 
some of the rhenium [19], ruthenium [20] and palladium [21] complexes with 5-nitrofuryl 
pharmacophore containing thiosemicarbazones as ligands have proven to be more active 
against T. cruzi than the corresponding free ligands. 
 
In the last decades, a large number of organometallic compounds have attracted great 
interest because of their broad spectra of biological and pharmacological properties [22-25]. 
In particular, metallocene-based chemotherapeutics are known to exhibit a wide diversity of 
biological activity [26,27]. Among them, ferrocenyl compounds have emerged as an 
important research field in the on-going discovery of metallo-therapeutic agents (i.e., 
antibacterial, antitumor, antimalarial, and antitrypanosomal activities) [28-31]. Promising 
results have been reported when targeting diseases such as cancer and malaria, indicating 
that the incorporation of a ferrocenyl fragment may enhance biological activities or 
generate new medicinal properties [32-36]. Additionally, the chemistry of cyrhetrene, 
[Re(η5-C5H5)(CO)3] (the typical example of a three-legged half-sandwich rhenium(I) 
complex), has undergone rapid development in the last decade [37]. Among its many other 
applications, this organometallic core has been recognized as a promising anticancer drug 
candidate [38]. For example, Re-Tamoxifen has been demonstrated to be slightly more 
active than Tamoxifen for the treatment of hormone-responsive breast tumors [39]. 
Recently, the cyrhetrenyl fragment was conjugated to sulfonamide moieties to target human 
carbonic anhydrases [40] and has also been incorporated into several pharmacophores for 
evaluation as potential antimalarial agents [41]. 
 
In recent years, our research group has been involved in the development of ferrocene 
and cyrhetrene derivatives bound covalently to 5-nitrofurane and 5-nitrothiophene groups 
as a new class of antichagasic compounds. So far, we have connected the organometallic 
and 5-nitro heterocyclic groups through conjugated an non-conjugated bridges. We have 
established the existence of a relationship between el ctronic effects of the organometallic 
















In view of the aforementioned potential applications of 5-nitro-heterocyclic groups 
containing organometallic fragments, in this paper w  would like to report the synthesis and 
characterization, including the X-ray crystallography, of an unreported cyrhetrenylaniline 
and a new series of bioorganometallics possessing: i) electron-donor ferrocenyl and 
electron-withdrawing cyrhetrenyl groups; ii) an iminophenyl bridge and, iii) a thiophene 
ring substituted with a nitro group in the 4- and 5-position. In addition, in the present work, 







 All manipulations were conducted under a nitrogen atmosphere using Schlenk 
techniques. The complexes cyrhetrene [44], 4-nitrophenylferrocene (1b) [45] and 4-
ferrocenylaniline (2b) [46] were synthesized as described in the literature. Ferrocene 
(98%), 2-thiophenecarboxaldehyde (98%), 5-nitro-2-thiophenecarboxaldehyde (98%), 4-
nitroaniline (99%), sodium nitrite (99%), hexadecyltrimethylammonium bromide (99%), n-
BuLi 2.0 M, ZnCl2 anhydrous, PdCl2(PPh3)2 (99%), 1-bromo-4-nitrobenzene (99%), and 
KNO3 (99%) were purchased from Aldrich and used as such. Solvents were obtained 
commercially and purified using standard methods. FT-IR spectra were recorded in solution 
(CH2Cl2) or solid state (KBr disc) on a Thermo Scientific, model Nicolet FT-IR 
spectrophotometer in the range of 4000-500 cm-1. 1H and 13C NMR spectra were measured 
on a Bruker Advance 300 spectrometer using tetramethylsilane (TMS) as the internal 
standard and CDCl3 as a solvent. The following abbreviations were used to describe the 
peak patterns: s = singlet, d = doublet, t = triplet, and pst = pseudo-triplet.  Mass spectra 
were obtained on a Shimadzu model QP5050A GC-MS at the Laboratorio de Servicios 


















2.2. Synthesis of organometallic precursors 
 
2.2.1. Synthesis of the 4-cyrhetrenylaniline (2a) 
The preparation of the unreported 4-cyrhetrenylaniline complex was performed in two 
synthetic steps (Scheme 1), which involved first, a Negishi coupling reaction between 
cyrhetrene and 1-bromo-4-nitrobenzene and then the reduction of 4-nitrophenylcyrhetrene 
(1a).  
 
2.2.1.1. Synthesis of 4-nitrophenylcyrhetrene (1a) 
n-BuLi (0.30 mL, 2.0 M in cyclohexane, 0.64 mmol) was dded dropwise to a solution 
of cyrhetrene (100 mg, 0.30 mmol) in anhydrous THF (8.0 mL) at -78 °C. After that, the 
reaction mixture was stirred for 1.5 h at -78°C andZ Cl2 (48.0 mg, 0.35 mmol) was added. 
Subsequently, the mixture was allowed to warm to room temperature and was stirred for an 
additional 1.5 h. Then, a suspension of PdCl2(PPh3)2 (10.0 mg, 0.014 mmol) in dry THF 
(2.0 mL) and a solution of 1-bromo-4-nitrobenzene (BrC6H4NO2) (61.0 mg, 0.30 mmol) in 
dry THF (2.0 mL) were added to the reaction mixture and the stirring was continued, at 
room temperature, for 12 h. After this time, the soluti n was poured into water (10 mL) and 
extracted with dichloromethane (3 × 10 mL). The organic layers were dried over Na2SO4, 
filtered and evaporated under a vacuum. The complex (1a) was isolated as a pale yellow 
solid. The yield was 39% (45.0 mg, 0.12 mmol). IR (CH2Cl2, cm
-1): 2026, 1932 (νCO); 
1523, 1349 (νNO2). 1H NMR (CDCl3): δ 5.48 (t, 2H, J = 2.3 Hz, C5H4); 5.88 (t, 2H, J = 2.3 
Hz, C5H4); 7.54 (d, 2H, J = 8.9 Hz, C6H4); 8.21 (d, 2H, J = 8.9 Hz, C6H4). 
13C NMR 
(CDCl3): δ 83.4 (C5H4); 85.3 (C5H4); 103.4 (C5H4ipso); 124.4 (C6H4); 126.8 (C6H4); 139.3 
(C6H4); 147.5 (C6H4); 193.2 (CO). Mass spectrum (based on 
187Re) (m/z): 457 [M+]; 429 
[M+ - CO]; 401 [M+ - 2CO]; 373 [M+ - 3CO]. 
 
2.2.1.2. Synthesis of 4-cyrhetrenylaniline (2a) 
 First, 4-nitrophenylcyrhetrene (1a) (50.0 mg, 0.13 mmol) was added to a magnetically 
stirred solution of concentrated hydrochloric acid (0.40 mL) and ethanol (6.0 mL). Then 
granulated tin (75.0 mg, 0.63 mmol) was added and the reaction mixture was refluxed in a 















formed was treated with 3.0 mL of water and 10 mL of 0.5 M aqueous NaOH.  The solid 
crude product was extracted with CH2Cl2 (2 × 20 mL), dried over Na2SO4, filtered and the 
solvent was removed in a rotary evaporator. The solid thus obtained was crystallized in a 
mixture with CH2Cl2/hexane (1:5) at -18 °C. 2a was obtained as a dark orange solid in 47% 
yield (22.0 mg, 0.062 mmol). IR: (KBr, cm-1) 3440, 3339 (νNH2); (CH2Cl2, cm-1) 2020, 
1923 (νCO). 1H NMR (CDCl3): δ 3.76 (s, 2H, NH2); 5.35 (t, 2H, J = 2.2 Hz, C5H4); 5.64 (t, 
2H, J = 2.2 Hz, C5H4); 6.62 (d, 2H, J = 8.8 Hz, C6H4); 7.19 (d, 2H, J = 8.8 Hz, C6H4). 
13C 
NMR (CDCl3): δ 80.3 (C5H4); 84.1 (C5H4); 111.0 (C5H4ipso); 115.1 (C6H4); 121.5 (C6H4); 
127.7 (C6H4); 147.0 (C6H4); 194.6 (CO). Mass spectrum (based on 
187Re) (m/z): 427 [M+]; 
399 [M+ - CO]; 371 [M+ - 2CO]; 343 [M+ - 3CO]. 
 
 
 2.3. Synthesis of cyrhetrenyl and ferrocenyl imines. General procedure 
  
 The Schiff bases (Scheme 2) were achieved following the procedure reported by Zaheer 
et al. for the preparation of N-(arylidene)-4-ferrocenylaniline [47]. That is, 4-
cyrhetrenylaniline (2a) or 4-ferrocenylaniline (2b) and equimolar amounts of the 
corresponding (4 or 5)-nitro-thiophene-2-carboxaldehyde were dissolved in dry ethanol (10 
mL) and refluxed for 3 h in a nitrogen atmosphere. After this time, the solvent was 
evaporated under a vacuum and the colored solids obtained were crystallized with 
CH2Cl2/hexane (1:5) at -18 °C. 
 
2.3.1. N-(4-nitro-2-thiophenylidene)-4-phenylcyrhetrene (3a)  
 IR (KBr, cm-1):  2025 (s) (νCO), 1912 (vs) (νCO); 1617 (w) (νC=N). 1H NMR (CDCl3): 
δ 5.43 (t, 2H, J = 2.1 Hz, C5H4); 5.79 (t, 2H, J = 2.1 Hz, C5H4); 7.21 (d, 2H, J = 8.5 Hz, 
C6H4); 7.44 (d, 2H, J = 8.5 Hz, C6H4); 7.96 (d, 1H, J = 1.4 Hz, C4H2S); 8.42 (t, 1H, J = 1.4 
Hz, C4H2S); 8.55 (s, 1H, CH=N). 
13C NMR (CDCl3): δ 81.9 (C5H4); 84.7 (C5H4); 107.8 
(C5H4ipso); 121.8 (C6H4); 125.5 (C4H2S); 127.4 (C6H4); 130.9 (C4H2S); 150.9 (CH=N); 

















2.3.2. N-(5-nitro-2-thiophenylidene)-4-phenylcyrhetrene (4a) 
 The synthesis of complex 4a was carried out similarly to that described above (general 
procedure); nevertheless, the reflux was prolonged for 5 h. Brown crystals, yield: 56% 
(27.0 mg, 0.060 mmol). IR (KBr, cm-1): 2021 (s) (νCO), 1920 (vs) (νCO); 1618 (w) 
(νC=N). 1H NMR (CDCl3): δ 5.43 (t, 2H, J = 2.2 Hz, C5H4); 5.79 (t, 2H, J = 2.2 Hz, C5H4); 
7.24 (d, 2H, J = 8.7 Hz, C6H4); 7.39 (d, 1H, J = 4.3 Hz, C4H2S); 7.44 (d, 2H, J = 8.7 Hz, 
C6H4); 7.91 (t, 1H, J = 4.3 Hz, C4H2S); 8.55 (s, 1H, CH=N). 
13C NMR (CDCl3): δ 82.0 
(C5H4); 84.7 (C5H4); 107.5 (C5H4ipso); 121.9 (C6H4); 127.4 (C6H4); 128.7 (C4H2S); 129.9 
(C4H2S); 151.5 (CH=N); 194.0 (CO). Mass spectrum (based on 
187Re) (m/z): 566 [M+]; 482 
[M+ - 3CO]. 
 
2.3.3. N-(4-nitro-2-thiophenylidene)-4-phenylferrocene (3b) 
 Red solid, yield: 53% (40.0 mg, 0.10 mmol). IR (KBr, cm-1): 1617 (w) (νC=N). 1H 
NMR (CDCl3): δ 4.05 (s, 5H, C5H5); 4.35 (pst, 2H, C5H4, J = 1.8 Hz); 4.67 (pst, 2H, C5H4, 
J = 1.8 Hz); 7.21 (d, 2H, J = 8.5 Hz, C6H4); 7.51 (d, 2H, J = 8.5 Hz, C6H4); 7.94 (d, 1H, J = 
1.5 Hz, C4H2S); 8.40 (t, 1H, J = 1.5 Hz, C4H2S); 8.61 (s, 1H, CH=N). 
13C NMR (CDCl3): δ 
66.6 (C5H4); 69.4 (C5H4); 69.8 (C5H5); 121.5 (C6H4); 124.8 (C4H2S); 126.9 (C6H4); 130.6 
(C4H2S); 149.3 (CH=N). Mass spectrum (/z): 416 [M
+]. 
 
2.3.4. N-(5-nitro-2-thiophenylidene)-4-phenylferrocene (4b) 
 Green solid, yield: 25% (19.0 mg, 0.050 mmol). IR (KBr, cm-1): 1611 (w) (νC=N). 1H 
NMR (CDCl3): δ 4.07 (s, 5H, C5H5); 4.38 (pst, 2H, C5H4, J = 1.9 Hz); 4.70 (pst, 2H, C5H4, 
J = 1.9 Hz); 7.25 (d, 2H, J = 8.7 Hz, C6H4); 7.39 (d, 1H, J = 4.3 Hz, C4H2S); 7.54 (d, 2H, J 
= 8.7 Hz, C6H4); 7.94 (d, 1H, J = 4.3 Hz, C4H2S); 8.64 (s, 1H, CH=N). 
13C NMR (CDCl3): 
δ 66.7 (C5H4); 69.5 (C5H4); 69.9 (C5H5); 121.8 (C6H4); 126.9 (C6H4); 128.7 (C4H2S); 129.1 






















2.4.    X-ray crystal structure determinations 
  
 Single crystal X-ray diffraction studies have been successfully implemented for 2a, 4a 
and 3b. Table 1 summarized the fundamental crystal and refinement data for the 
compounds. Crystals of the cyrhetrenylaniline (2a) and imines (4a and 3b) were mounted 
using MiTeGen MicroMounts of a random orientation fr a single crystal X-ray diffraction 
experiment. The compounds were studied at room temperature on a Bruker D8 QUEST 
diffractometer equipped with a bidimensional CMOS Photon100 detector using graphite 
monochromated Mo-Kα radiation. The diffraction frames were integrated using the APEX2 
package [48] and were corrected for absorptions with SADABS [49]. The unit cell 
dimensions were determined by a least-squares fit reflection collected with I > 2s(I). Data 
were integrated and scaled using the APEX2 package and the scale correction was based on 
the equivalent reflection carried out using SADABS. The solution and refinement for 
compounds 2a, 4a and 3b were determined using Olex2 [50]. The 2a and 3b structures 
were solved using direct methods, while the 4a structure was solved by the Patterson 
Method, using ShelXS software for all the complexes [51] and a refinement package using 
Least Squares minimization. Calculations were performed with SMART software for data 
collection, while data reduction used ShelXL. The complete structures were refined using 
the full matrix least squares procedure on the reflection intensities (F2) with anisotropic 
thermal parameters for all the nonhydrogen atoms and all the hydrogen atoms were placed 




Crystal data and structure refinement results for 2a, 4a and 3b complexes. 
 
  Compound 2a  4a 3b  
   Empirical formula C14H10NO3Re  C19H11N2O5ReS C21H16N2O2SFe  
   Formula weight  426.44 565.56 416.27 
   Temperature  296.15 296.15 296.15 
   Wavelength  0.71073 0.71073 0.71073 
   Crystal system Orthorhombic  Triclinic Monoclinic 















   Unit cell dimensions  a = 18.6229(6) Å α = 90.00° a = 7.3225(15) Å α = 85.171°  a = 22.059(4) Å α = 90.00° 
  b = 6.1002(2) Å β = 90.00° b = 7.6762(15) Å β = 86.074°  b = 7.3959(10) Å β = 98.851° 
  c = 22.8140(8) Å γ = 90.00° c = 16.935(3) Å γ = 76.288°  c = 11.3482(17) Å γ = 90.00° 
  Volume Å3 2591.75(15) 920.3(3)  1829.3(5) 
   Z 8 2 4 
   Density (calculated)  (g/cm3) 2.186 2.041 1.511 
   Absorption coefficient (mm-1) 9.379 6.750 0.957 
   F(000) 1600.0 540.0 856.0 
   Theta range for data collection 4.189 - 52.42° 4.84 - 54.42°  5.6 - 53.26° 
   Index ranges 
-23 ≤ h ≤ 23, -7 ≤ k ≤ 7, -28 ≤ l ≤ 
28 
-9 ≤ h ≤ 9, -9 ≤ k ≤ 9, -21 ≤ l ≤ 21 
-27 ≤ h ≤ 27, -9 ≤ k ≤ 9, -14 ≤ l ≤ 
14 
   Reflections collected 105015 50340 33224 
   Independent reflections  2604 [Rint = 0.0485] 4084 [Rint = 0.0659] 3825 [Rint = 0.0351] 
   Completeness θ = 26.2°, 99% θ = 27.2°, 99% θ = 26.6°, 99% 
   Max. and min. Transmission Tmax = 0.745 and Tmin= 0.551     Tmax = 0.700 and Tmin= 0.562      Tmax =0.954 and Tmin= 0.784        
   Refinement method Least Squares minimisation. Least Squares minimisation. Least Squares minimisation. 
   Data/restraints/parameters 2604/0/180 4084/0/253  3825/0/244 
   Goodness-of-fit on F2 1.188 1.084 1.034 
   Final R indices [I > 2 (I)] R1 = 0.0283, wR2 = 0.0433 R1 = 0.0266, wR2 = 0.0501  R1 = 0.0366, wR2 = 0.0907 
   R indices (all data) R1 = 0.0387, wR2 = 0.0450 R1 = 0.0384, wR2 = 0.0532  R1 = 0.0566, wR2 = 0.1037 
        
 
 
2.5. Cyclic voltammetry (CV) 
 
 DMSO (spectroscopy grade) was used as a solvent and w s obtained from Aldrich. 
Tetrabutylammonium perchlorate (TBAP), which was used as supporting electrolyte, was 
obtained from Fluka. CV measurements were obtained using a Metrohm 693 VA 
instrument with a 694 VA Stand convertor and a 693 VA Processor, in DMSO (ca. 1.0 × 
10-3 mol L-1), using TBAP (ca. 0.1 mol L-1), under a nitrogen atmosphere at room 
temperature, using a three electrode cell. A hanging mercury drop electrode was used as the 
working electrode (HMDE), a platinum wire as the auxiliary electrode and a saturated 





















2.6. Biological Evaluation 
 
2.6.1. Cell culturing 
 
 L6 rat skeletal myoblasts were grown at 37 °C under a 5 % (v/v) CO2 atmosphere in 
RPMI-1640 medium supplemented with 20 mM HEPES pH 7.4, 2 mM sodium glutamate, 
2 mM sodium pyruvate, 2.5 U mL-1 penicillin, 2.5 mg mL-1 streptomycin and 10 % (v/v) 
foetal calf serum (Pan Biotech UK Ltd).  
 T. brucei brucei BSF trypomastigotes (MITat 427 strain; clone 221a) were grown at 37 
°C under a 5 % (v/v) CO2 atmosphere and cultured in HMI-9 media (Life Technologies 
Ltd) supplemented with 36 mM sodium bicarbonate, 0.014 % (v/v) β-mercaptoethanol and 
10 % (v/v) heat-inactivated foetal calf serum (Pan Biotech UK Ltd) [52,53].  
 
 
2.6.2. Anti-proliferative assays 
 
 The following growth inhibition assays were carried out in a 96-well plate format. L6 rat 
skeletal myoblasts or T. brucei brucei BSF trypomastigotes were seeded at 1.0 × 104 cells 
mL-1 in 200 µL growth medium containing different concetrations of compound. The 
compounds were prepared in 10 mM stock solutions in 100% DMSO and stored at -20 °C. 
After incubation at 37 °C for 6 (L6 cells) and 3 (T. b. brucei) days, resazurin (Aldrich) was 
added to each well at a final concentration of 12.5 µg mL-1 (or 2.5 µg per well). The plates 
were further incubated at 37 °C for 8 h (L6 cells and T. b. brucei) before measuring the 
fluorescence of each culture using a Gemini Fluorescent Plate reader (Molecular Devices) 
set at λEX = 530 nm and λEM = 585 nm with a filter cut off at 550 nm. The change in 
fluorescence resulting from the reduction of resazurin is proportional to the number of live 
cells. The compound concentration that inhibits thecell growth by 50% (EC50) was 




















3. Results and discussion 
 
3.1. Design and synthesis  
 
As part of our continued interest in the study on the electronic influence of the 
organometallic groups into hybrid organic-organometallic imines compounds with potential 
antiparasitic activity, we decided to form new Schiff bases containing a [-C6H4-N=CH-] 
bridge between the organometallic entity and 4- and5-nitro-2-thiophenyl groups. To do 
that we inspired on the several reports dealing with imines derived from ferrocenylanilines, 
which have proved to be excellent and versatile building blocks with the ability to produce 
several compounds with interesting electrochemical [54], antimicrobial [55-58], antioxidant 
[59] and antitumoral properties [60,61]. On the other and, we selected the nitro-thiophenyl 
group substituted into the 4- and 5-position because they allowed us to compare the 
reduction potential of the nitro group and the anti-T. brucei activity. Since ferrocenylaniline 
is a known compound [46, 62-64], our first goal was the synthesis of the analogous 
cyrhetrene derivative (2a), which was prepared following a modified procedure reported for 
ferrocenylaniline. The first step involved the preparation of 4-nitrophenylcyrhetrene (1a) by 
a Negishi cross-coupling reaction between cyrhetren and 1-bromo-4-nitrobenzene, 
following a strategy similar to that reported for 2-pyridylcyrhetrene [65], followed by its 
reduction with tin in hydrochloric acid [46] (see Scheme 1). Compound 2a was isolated in 
low yield and characterized by spectroscopic and crystallographic techniques. 
 
In the IR spectrum, 2a showed N-H stretching absorption bands at 3440 and 3339 cm-1 
(in KBr) which are similar to those reported for 4-ferrocenylaniline [46]. As expected, the 
ν(CO) bands observed at 2020 and 1923 cm-1 (in CH2Cl2) are shifted to low energy 
compared to the ones measured for 1a, due to the electron-donor capability of the NH2 
group. The 1H NMR spectrum of 2a showed the resonances for the C5 ring at 5.35 and 5.64 
ppm, whereas the NH2 and aryl hydrogen’s resonances deferred by about 0.1 ppm with 
those reported for ferrocenylaniline [64]. The 13C NMR spectra of the compound showed 
signals at 80.3, 84.1 and 111.0 ppm, which is indicative of a monosubstituted cyrhetrene 















experimental chemical shift with those measured for their ferrocenyl analogue [64]. The X-







Scheme 1. Synthesis of 4-cyrhetrenylaniline (2a): (a) n-BuLi, THF, -78°C, 1.5 h; (b) 
ZnCl2, -78 °C, 1.5 h; (c) PdCl2(PPh3)2, 1-bromo-4-nitrobenzene, 12 h; (d) HCl, Sn, EtOH, 
reflux, 4 h. 
 
 
To prepare the Schiff bases described below, we synthesized the unreported 4-nitro-2-
thiophenecarboxaldehyde, which was prepared by nitration of thiophenecarboxaldehyde 
according to the procedure described by Fabrichnyi et al. [66] (Supplementary Material). 
 
The organometallic imines derived from 4- and 5-nitrothiophene were obtained as 
described in Scheme 2, following the same procedure reported for some N-(arylidene)-4-
ferrocenylaniline [58-61,67,68], that is, by the reaction of the appropriate organometallic 
amine (2a or 2b) and the corresponding 4- or 5-nitrothiophenecarboxaldehyde in anhydrous 
EtOH. All compounds were isolated in low to moderat yields as pure material (by NMR), 
after crystallization from the CH2Cl2/hexane mixture. They were air stable and soluble in 





















Scheme 2. Synthesis of cyrhetrenyl and ferrocenyl imines derived from 4- and 5-
nitrothiophene. 
 
In all cases, the infrared spectral analysis of these compounds showed the characteristic 
absorption corresponding stretching vibration of the ν(C=N) bond in the range of 1611–
1618 cm−1 in KBr disk. Similar ν(C=N) frequency values have been previously reported for 
other organometallic Schiff bases derived from 5-nitrothiophene [43]. The absence of the 
band assigned to the aldehyde carbonyl group of nitro-heterocycle as well as the (N-H) 
stretching absorption of the amine precursors confirmed the formation of the 
organometallic imines. In addition, the cyrhetrenylimines (3a) and (4a) exhibited the 
characteristic ν(CO) absorption bands, in the region of 2025 and 1912 cm-1.  
 
For all complexes, the 1H NMR spectra showed only the presence of a single compound. 
As expected, the 1H NMR spectra of the ferrocenyl derivatives (3b) and (4b) exhibited a 
singlet at δ 4.0 and two resonances between 4.35–4.70 ppm, which were assigned to the 
protons of the ferrocenyl group. Similarly, the two resonances for the cyrhetrenyl group in 
compounds (3a) and (4a) were observed at identical chemical shifts (5.43 and 5.79 ppm). 
In all cases, the aryl hydrogen’s were observed as oublets in the range 7.21–7.54 ppm. The 
most interesting feature of the 1H NMR spectra of these Schiff bases was (i) the imine 
proton of the cyrhetrenyl derivatives are slightly upfield when compared to the ferrocenyl 
analogues, and (ii) the heterocyclic hydrogen atoms were observed in a higher field (7.94–
8.42 ppm) and showed smaller coupling constants (1.4–1.5 Hz) when the nitro group was at 
the 4-position (3a-b) compared to their 5-substituted analogues (7.39–7.94 ppm, J = 4.3 
Hz), meaning that they follow the same trend observed in the nitro-
thiophenecarboxaldehyde precursors. 
 
The 13C NMR data also indicated the existence of a single compound. Despite that, these 
types of compounds could adopt two different forms (E- or Z-) and their 1H and 13C NMR 
spectra agreed with those reported for the related ferrocenyl and cyrhetrenyl Schiff bases 















Further proof was provided by an X-ray crystal structure determination of (4a) and (3b) 
(see below). The most important feature of these spectra is the presence of low field 
resonance (δ 149–151) assigned to the iminyl carbon. This resonance occurs at almost the 
same δ as those reported for other Schiff bases [55,58] and were corroborated by 1H–13C 
NMR HMQC and HSQC. It is important to note that the13C shifts of the iminyl carbons of 
these nitrothiophene derivatives did not show a clear dependence on the electronic 
properties of the organometallic substituents in the side chain and the position of the nitro 
group in the thiophene ring. We previously observed similar results in other imines 
containing 5-nitrothiophene groups [43]. 
 
 
3.2. X-ray crystallography 
  
A single crystal of cyrhetrenyaniline (2a) was grown by slow evaporation of the 
CH2Cl2/hexane solution containing the product. The ORTEP diagram of the molecule 
giving its numbering scheme is shown in Fig. 1. The summary of the structural refinement 
data is included in Table 1 and the bond lengths and bond angles are provided as 
supplementary materials (Tables S1). Also, 2a was shown to crystallize in the 














Figure 1. Molecular structure of 2a drawn with 30% probability displacement ellipsoids. 



















The molecular structure of compound 2a [{( η5-C5H4)-(C6H4-4-NH2)}Re(CO)3] (Fig. 1) 
was confirmed by X-ray diffraction studies showing the expected three-legged piano-stool 
structure and the presence of an aniline unit attached to the C5H4 ring. Average values of 
the Re-CO (1.907 Å) and C-O (1.146 Å) bond lengths and the Re centroid distance 
(1.961(2) Å) are similar to those reported for [{(η5-C5H4)-2-(C5H4N)}Re(CO)3] [65]. The 
short C(1)-C(6) (1.473(6) Å) bond length on 2a does suggest enhanced conjugation 
between the NH2 on the phenyl and the C5H4 ring. This was also supported by the torsion 
angles (C(2)-C(1)-C(6)-C(11), 0.5(6)°), which indicate that the C5H4 ring and the aromatic 
group are almost co-planar allowing for efficient overlap of the π-electrons for bonding. 
Similar findings have been reported by Coville for ferrocenylaniline [62].  
 
To compare the structural parameters of the organometallic Schiff bases with the 
crystallographic data reported for the related compunds [55,58,60,67], single-crystal X-ray 
diffraction studies were successfully carried out for [{(η5-C5H4)-C6H4-N=CH-(C4H2S-5-
NO2)}Re(CO)3] (4a) and [{(η5-C5H4)-C6H4-N=CH-(C4H2S-4-NO2)}Fe(η5-C5H5)] (3b). 
The molecular structures of 4a and 3b are shown in Figs. 2 and 3, respectively, including 
the selected bond lengths and bond angles. A full description of the bond lengths and bond 
angles are listed in Table S2 and S3 in the Supplementary Material.   
 
The crystallographic structures of compounds 4a and 3b showed that the (C4H2S) 
moiety and [(η5-C5H4)-(C6H4)] unit are in a trans arrangement, thus confirming that these 
imines also adopt the E form in the solid state. In addition, for imine 3b, the presence of the 



























Figure 2. Molecular structure of 4a drawn with 30% probability displacement ellipsoids. 
Selected bond lengths (Å) and bond angles (°): C5H4(centroid)–Re 1.959(18); C(1)–C(6) 
1.488(5); N(1)–C(9) 1.413(5); N(1)–C(12) 1.259(5); C(12)–C(13) 1.445(5); C(13)–C(14) 
1.371(6); C(14)–C(15) 1.397(6); C(15)–C(16) 1.357(6); N(2)–C(16) 1.431(5); O(1)–N(2) 
1.229(5); O(2)–N(2) 1.218(5). C(2)–C(1)–C(6) 125.9(4); C(1)–C(6)–C(11) 120.1(3); 





























Figure 3. Molecular structure of 3b drawn with 30% probability displacement ellipsoids. 
Selected bond lengths (Å) and bond angles (°): C5H4(centroid)–Fe 1.6438(12), 
C5H5(centroid)–Fe 1.6487(16); C(1)–C(6) 1.469(4); N(1)–C(9) 1.412(3); N(1)–C(12) 
1.268(3); C(12)–C(13) 1.440(4); C(13)–C(14) 1.359(3); C(14)–C(15) 1.406(4); C(15)–
C(16) 1.350(3); N(2)–C(15) 1.463(3); O(1)–N(2) 1.214(3); O(2)–N(2) 1.218(3). C(2)–
C(1)–C(6) 127.6(2); C(1)–C(6)–C(11) 122.0(2); C(10)–C(9)–N(1) 125.3(2); C(9)–N(1)–
C(12) 122.3(2); N(1)–C(12)–C(13) 120.1(2); C(12)–C(13)–S(1) 118.34(18).  
 
 
The cyrhetrenyl group of structure 4a exhibited a typical three-legged piano-stool 
structure (Fig. 2), which is commonly observed for other half-sandwich rhenium(I) 
complexes studied by X-ray crystallography [43,69,70]. In 3b (Fig. 3), the ferrocenyl 
fragment adopted an eclipsed conformation, similar to that found in many other 
monosubstituted ferrocenyl derivatives [55,71]. The distances Fe···centroid of the “C5H4” 
and "C5H5" rings were similar to those found for these type of compound [57,67].  
 
The most interesting structural features of these organometallic imine compounds are: (i) 
in 4a and 3b the substituted cyclopentadienyl ring and the phenyl moiety showed a low 
degree of co-planarity with a dihedral angle (planes C(1)–C(5) and C(6)–C(11)) of 
33.35(15)° and 17.35(11)°, respectively. Similar behaviour was found between the planes 
of substituted Cp and the thiophene (dihedral angles [C(1)-C(5)] and the [C(13)-C(16)-
S(1)], of 51.20(16)° in 4a and 50.02(11)° in 3b). Therefore, an efficient electronic 
delocalization through the (η5-C5H4-C6H4-C4H2S-NO2) system is impeded, (ii) the torsion 
angle (τ) between the imine group and the nitroheterocycle fragment {[N(1)-C(12)-C(13)-
S(1)] is 2.8(5)° in 4a and 6.2(3)° in 3b} are indicative of a high degree of coplanarity; 
therefore, a greater electronic delocalization can be expected between these groups, (iii) 
bond lengths of N(1)-C(9), N(1)-C(12) and C(1)-C(6) are similar to those reported for other 
Schiff bases derived from ferrocenylaniline [55,67] (iv) the iminic double bond N(1)-C(12) 
in 4a (1.259(5) Å) was slightly shorter than the one measured for 3b (1.268(4) Å), which 
suggests a reduced delocalization between the imine group and the heterocyclic entity in 

































C(16)-N(2)] of the 5-nitrothiophene group (4a) are shorter than the ones found in the 4-
nitro derivative (3b) [C(14)-C(15) and C(15)-N(2)]. This finding is probably due to a 
higher electronic conjugation (by resonance) between th  thiophene and nitro group at the 
5-position, in comparison with its 4-nitrothiophene analogue.     
 
 
3.3. Electrochemical studies  
 
To establish the possible correlation between the electronic effects of the phenylimine 
bridge with their E1/2 and trypanocidal activity, we measured the reduction p tentials of 
nitro compounds by cyclic voltammetry. The large amount of electrochemical information 
available in the literature for 5-nitroheterocycles (furane and thiophene) [72-74] contrasts 
with the limited studies dealing with nitrothiophenes and nitrofuranes nitrated in different 
ring positions [75]. For that reason, in this study we compared the reduction potential of 4-
nitro (3a, 3b) and 5-nitro (4a, 4b) thienyl derivatives.   
  
Under the recommended experimental conditions [74], the 4-nitro derivatives exhibit a 
different cathodic performance to that observed for their isomeric analogues (5-nitro). For 
example, Figure 4 shows the comparative cyclic voltammograms of compounds 3a and 4a. 
It is important to mention that the electrochemical p rameters obtained for all compounds 














































Figure 4. (i) Cyclic voltammogram of compounds 3a and (ii) Cyclic voltammogram of 
compounds 4a in DMSO of 0.1 to 2.5 Vs-1. 
 
 
The voltammograms obtained for 4-nitro compounds (3a and 3b) show the presence of 
only one reduction peak with a potential near -1.0 V. This wave was correlated to an one-
electron transfer process due to the reduction of the nitro group to the nitro radical anion 
[76a]. According to the Nicholson diagnostic criteria, a quasi-reversible reduction process 
should be involved [76b]. Both the shape of voltammograms and the displacement of the 
wave to cathodic potentials can be correlated to similar results observed by Sarragiotto and 
co-workers in nitro aromatic systems derived from tetrahydro-β-carbolines [76a]. On the 
other hand, 5-nitro derivatives (4a and 4b) exhibited two reduction cathodic peaks in their 
voltammograms, similar to those observed in several organometallic Schiff bases derived 
from 5-nitrofuran and 5-nitrothiophene [42,43]. The first one, observed at -0.65 V, was 
attributed to the nitro/nitro-radical anion couple [74,77] (comparatively lower than those 
obtained for 4-nitro derivatives). According to the standard reversibility criteria, this couple 
corresponded to a reversible diffusion-controlled single electron transfer. The second 
irreversible peak displayed a more negative reduction potential (≈ -1.1 V), which was 
assigned to the electroreduction of the nitro-radicl anion to form a hydroxylamine 
derivative (this reduction wave is not observed in the 4-nitro derivatives in the potential 
range used) [77].  
 
Taking into account the electrochemical behaviour fr all the compounds, it is possible 
to make some general conclusions: (i) in the two serie  of compounds (4-nitro and 5-nitro) 
the E1/2 values [E1/2 = (Ea + Ec)/2]  (Table 2)  did not correlated with the electronic nature 
of the organometallic fragment attached to the phenylimine bridge, suggesting that there is 
no electronic communication between the two substituents of the imine group, which is 
probably due to the lack of planarity of the phenylimine bridge with the organometallic and 















lower E1/2 values than nifurtimox and 4-nitroderivatives, under the same conditions, 
indicating that these compounds had a better ability to generate radical species [74]. These 
results are in agreement with the studies (DFT calcul tions, cyclic voltammetry and 




Table 2. In vitro anti-T. brucei activity, cytotoxicity in L6 cells, selectivity index and  
reduction potentials of cyrhetrenyl (3a, 4a) and ferrocenyl (3b, 4b) imines. 
Compound Structrure 
EC50 (µM)





d                 
(NO2 group) T. brucei  L6 L6/T. b. brucei 
3a 4-NO2 16.32 ± 1.72 20.77 ± 3.71 1.27 -0.980 
4a 5-NO2 0.44 ± 0.01 13.27 ± 1.58 30.2 -0.560 
3b 4-NO2 9.77 ± 1.21 9.22 ± 1.90 0.94 -0.985 
4b 5-NO2 2.72 ± 0.45 >150 >55.1 -0.590 
Nfx 5-NO2 3.65 ± 0.16 88.67 ± 3.49 24.3 -0.880
e 
a EC50: concentration that inhibits 50% of growth. Values shown are the average of four 
 or more  experiments. 
b Standard error (SE). 
c The selectivity index was calculated as a ratio of the [EC50 L6 cells : EC50  T.b. brucei]. 
d E1/2: (Epc + Epa)/2. 
e Data From Ref. [74].  
  Nfx: nifurtimox 
 
 
3.4. In vitro anti-T. brucei activity  
 
To evaluate the anti-trypanosomal activity by modifying the position of the nitro group 
attached to the thiophene ring (4-NO2 and 5-NO2), we undertook an in vitro growth 
inhibitory study of all the compounds against T. brucei brucei BSF trypomastigotes and rat 
skeletal myoblasts (L6 cells) using standard drug screens. From the resultant dose-response 
curves (cell viability (%) vs Log[compound]), the EC50 values in µM were determined for 
all organometallic imines. The EC50 values are provided in Table 2 and compared against 
















From the data depicted in Table 2, some general observations can be achieved. Firstly, 
there was not a linear correlation between the nitro-reduction (E1/2) with the anti-T. brucei 
activity (EC50). Similar results have been previously reported for related nitrothiophene 
compounds with antichagasic activity [43]. Second, 5-nitrothiophenes are more efficient 
anti-T. brucei agents (EC50 = 0.44 for 4a and EC50 = 2.72 µM for 4b) than their 4-nitro 
analogues (EC50 = 16.32 for 3a and 9.77 µM for 3b). These results are probably related to 
the generation (in agreement with the electrochemical results) and a better stabilization of 
the anion nitro radical (NO2
._) in the biological target [5,11,78-80]. Third, the cyrhetrenyl 
derivative containing the 5-nitrothiophene (4a) was a more potent trypanocidal agent than 
the ferrocenyl analogue (4b) possibly due to the better lipophilicity of the cyrhetrenyl 
compared to ferrocenyl fragment [41b]. Four, independent of the substitution on the 
thiophene ring, the cyrhetreny derivatives (3a and 4a) showed comparable cytotoxicity, 
whereas the ferrocenyl containing the 5-nitrothiophenyl ring (4b) is less cytotoxic than its 
4-nitro analogue (3b) and nifurtimox. Lastly, the Selectivity Index (SI) calculated as the 
ratio between the EC50 values of L6 cell and T. brucei (Table 2) demonstrated that the 
organometallic compounds derived from 5-nitrothiophene, 4a and 4b, (SI = 30.2 and >55, 
respectively) have improved selectivity against theparasite than nifurtimox (SI = 24.3). 
Therefore, these new organometallic compounds could represent a promising family for the 




4. Conclusion  
 
New organometallic phenylimines derived from 4- and 5-nitrothiophene were 
synthesized and characterized. Like many other organ metallic Schiff bases, these 
compounds adopt an anti-configuration for the iminyl fragment in solution and in the solid 
state. Cyclic voltammetry studies demonstrated that phenylimines derived from 5-
nitrothiophene presented reduction potentials of the NO2 group (E1/2 ≈ -0.575 V) that were 
more anodic than those registered for their 4-nitro analogues (E1/2 ≈ -0.982 V) and 















indicated that the most active complexes are those p sessing the 5-nitrothiophene moiety, 
such as 4a, which is 8-fold more active than nifurtimox, whereas complex 4b was more 
active and less toxic to host L6 cells than nifurtimox. The non-coplanarity of the [(η
5-C5H4)-
C6H4-N=CH-(C4H2S)] system impeded the fluid electronic communication between the 
cyrhetrenyl and ferrocenyl fragments with the nitrothi phene groups. Accordingly, the 
electronic effects of the organometallic units are not influential factors in E1/2 and the anti-
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Appendix A. Supplementary data  
 
CCDC 1586086-1586088 contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from the Cambridge Crystallographic Data 
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Unreported cyrhetrenylaniline was synthetized and fully characterized, including X-ray 
crystallography. 
 
Cyrhetrenyl and ferrocenyl phenylimines derived from 4-nitro and 5-nitrothiophene have 
been designed and prepared. 
 
The anti-T. brucei activity showed that 5-nitrothiophene derivatives were more potent 
trypanocidal agents compared to their 4-nitrothiophene analogs 
